Selected research
Industry Research
Personalized Psychiatry Industry Research Report 2026
Market perspective
The global Personalized Psychiatry market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Personalized Psychiatry market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Personalized Psychiatry market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Personalized Psychiatry market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Personalized Psychiatry include COMPASS Pathways, Mindstrong Health, Pear Therapeutics, Cogito, Kaia Health, Sooma, GenoMind, Empatica and Akili Interactive and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Personalized Psychiatry market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Personalized Psychiatry.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Personalized Psychiatry Market by Company
COMPASS Pathways
Mindstrong Health
Pear Therapeutics
Cogito
Kaia Health
Sooma
GenoMind
Empatica
Akili Interactive
Neuroverse
Personalized Psychiatry Segment by Type
Depression and Anxiety
Bipolar Disorder
Addiction
Other
Personalized Psychiatry Segment by Application
Mental Health Professionals
Patients
Healthcare Providers
Personalized Psychiatry Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Personalized Psychiatry market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Personalized Psychiatry and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Personalized Psychiatry.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Personalized Psychiatry companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Depression and Anxiety
- Bipolar Disorder
- Addiction
- Other
Applications
- Mental Health Professionals
- Patients
- Healthcare Providers
Companies covered
- COMPASS Pathways
- Mindstrong Health
- Pear Therapeutics
- Cogito
- Kaia Health
- Sooma
- GenoMind
- Empatica
- Akili Interactive
- Neuroverse
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Personalized Psychiatry by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Depression and Anxiety
- 2.2.3 Bipolar Disorder
- 2.2.4 Addiction
- 2.2.5 Other
- 2.3 Personalized Psychiatry by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Mental Health Professionals
- 2.3.3 Patients
- 2.3.4 Healthcare Providers
- 2.4 Assumptions and Limitations
3 Personalized Psychiatry Breakdown Data by Type
- 3.1 Global Personalized Psychiatry Historic Market Size by Type (2021-2026)
- 3.2 Global Personalized Psychiatry Forecasted Market Size by Type (2027-2032)
4 Personalized Psychiatry Breakdown Data by Application
- 4.1 Global Personalized Psychiatry Historic Market Size by Application (2021-2026)
- 4.2 Global Personalized Psychiatry Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Personalized Psychiatry Market Perspective (2021-2032)
- 5.2 Global Personalized Psychiatry Growth Trends by Region
- 5.2.1 Global Personalized Psychiatry Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Personalized Psychiatry Historic Market Size by Region (2021-2026)
- 5.2.3 Personalized Psychiatry Forecasted Market Size by Region (2027-2032)
- 5.3 Personalized Psychiatry Market Dynamics
- 5.3.1 Personalized Psychiatry Industry Trends
- 5.3.2 Personalized Psychiatry Market Drivers
- 5.3.3 Personalized Psychiatry Market Challenges
- 5.3.4 Personalized Psychiatry Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Personalized Psychiatry Players by Revenue
- 6.1.1 Global Top Personalized Psychiatry Players by Revenue (2021-2026)
- 6.1.2 Global Personalized Psychiatry Revenue Market Share by Players (2021-2026)
- 6.2 Global Personalized Psychiatry Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Personalized Psychiatry Head Office and Area Served
- 6.4 Global Personalized Psychiatry Players, Product Type & Application
- 6.5 Global Personalized Psychiatry Manufacturers Established Date
- 6.6 Global Personalized Psychiatry Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Personalized Psychiatry Market Size (2021-2032)
- 7.2 North America Personalized Psychiatry Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Personalized Psychiatry Market Size by Country (2021-2026)
- 7.4 North America Personalized Psychiatry Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Personalized Psychiatry Market Size (2021-2032)
- 8.2 Europe Personalized Psychiatry Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Personalized Psychiatry Market Size by Country (2021-2026)
- 8.4 Europe Personalized Psychiatry Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Personalized Psychiatry Market Size (2021-2032)
- 9.2 Asia-Pacific Personalized Psychiatry Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Personalized Psychiatry Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Personalized Psychiatry Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Personalized Psychiatry Market Size (2021-2032)
- 10.2 South America Personalized Psychiatry Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Personalized Psychiatry Market Size by Country (2021-2026)
- 10.4 South America Personalized Psychiatry Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Personalized Psychiatry Market Size (2021-2032)
- 11.2 Middle East & Africa Personalized Psychiatry Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Personalized Psychiatry Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Personalized Psychiatry Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 COMPASS Pathways
- 12.1.1 COMPASS Pathways Company Information
- 12.1.2 COMPASS Pathways Business Overview
- 12.1.3 COMPASS Pathways Revenue in Personalized Psychiatry Business (2021-2026)
- 12.1.4 COMPASS Pathways Personalized Psychiatry Product Portfolio
- 12.1.5 COMPASS Pathways Recent Developments
- 12.2 Mindstrong Health
- 12.2.1 Mindstrong Health Company Information
- 12.2.2 Mindstrong Health Business Overview
- 12.2.3 Mindstrong Health Revenue in Personalized Psychiatry Business (2021-2026)
- 12.2.4 Mindstrong Health Personalized Psychiatry Product Portfolio
- 12.2.5 Mindstrong Health Recent Developments
- 12.3 Pear Therapeutics
- 12.3.1 Pear Therapeutics Company Information
- 12.3.2 Pear Therapeutics Business Overview
- 12.3.3 Pear Therapeutics Revenue in Personalized Psychiatry Business (2021-2026)
- 12.3.4 Pear Therapeutics Personalized Psychiatry Product Portfolio
- 12.3.5 Pear Therapeutics Recent Developments
- 12.4 Cogito
- 12.4.1 Cogito Company Information
- 12.4.2 Cogito Business Overview
- 12.4.3 Cogito Revenue in Personalized Psychiatry Business (2021-2026)
- 12.4.4 Cogito Personalized Psychiatry Product Portfolio
- 12.4.5 Cogito Recent Developments
- 12.5 Kaia Health
- 12.5.1 Kaia Health Company Information
- 12.5.2 Kaia Health Business Overview
- 12.5.3 Kaia Health Revenue in Personalized Psychiatry Business (2021-2026)
- 12.5.4 Kaia Health Personalized Psychiatry Product Portfolio
- 12.5.5 Kaia Health Recent Developments
- 12.6 Sooma
- 12.6.1 Sooma Company Information
- 12.6.2 Sooma Business Overview
- 12.6.3 Sooma Revenue in Personalized Psychiatry Business (2021-2026)
- 12.6.4 Sooma Personalized Psychiatry Product Portfolio
- 12.6.5 Sooma Recent Developments
- 12.7 GenoMind
- 12.7.1 GenoMind Company Information
- 12.7.2 GenoMind Business Overview
- 12.7.3 GenoMind Revenue in Personalized Psychiatry Business (2021-2026)
- 12.7.4 GenoMind Personalized Psychiatry Product Portfolio
- 12.7.5 GenoMind Recent Developments
- 12.8 Empatica
- 12.8.1 Empatica Company Information
- 12.8.2 Empatica Business Overview
- 12.8.3 Empatica Revenue in Personalized Psychiatry Business (2021-2026)
- 12.8.4 Empatica Personalized Psychiatry Product Portfolio
- 12.8.5 Empatica Recent Developments
- 12.9 Akili Interactive
- 12.9.1 Akili Interactive Company Information
- 12.9.2 Akili Interactive Business Overview
- 12.9.3 Akili Interactive Revenue in Personalized Psychiatry Business (2021-2026)
- 12.9.4 Akili Interactive Personalized Psychiatry Product Portfolio
- 12.9.5 Akili Interactive Recent Developments
- 12.10 Neuroverse
- 12.10.1 Neuroverse Company Information
- 12.10.2 Neuroverse Business Overview
- 12.10.3 Neuroverse Revenue in Personalized Psychiatry Business (2021-2026)
- 12.10.4 Neuroverse Personalized Psychiatry Product Portfolio
- 12.10.5 Neuroverse Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst